HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Earnings In Brief

This article was originally published in The Rose Sheet

Executive Summary

Alberto Culver: Firm attributes impressive first quarter of fiscal 2008 in part to double-digit sales growth for TRESemmé in all markets, including new regions Mexico, Latin America and South Africa. Net sales for the first quarter came in at $400.7 mil., up 14.1% compared with the prior-year period, according to Jan. 28 statement. Nexxus also posted solid S&E growth; Alberto-Culver will enhance the Nexxus marketing and product mix in the U.S. and consider launching the brand in new markets, President and CEO V. James Marino said during Jan. 28 earnings call. Alberto VO5 sales increased in the low single digits overseas and were flat in the U.S., with growth in company's opening price point business offset by discontinued products, exec said. St. Ives experienced low single-digit sales growth due to uptick in some international markets and the effect of foreign exchange. Firm will launch a new skin-care line, St. Ives Elements, in March. Pre-tax income from continuing operations reached $43.5 mil., versus a loss of $1.3 mil. in the same period a year ago. Company notes that it incurred costs of $4.8 mil. related to reorganization following its separation from Sally Beauty Holdings and the Oct. 29, 2007 closure of its manufacturing facility in Toronto, Canada (1"The Rose Sheet" Jan. 21, 2008, p. 7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel